Hours before the U.S. Senate recessed for the remainder of summer 2017, legislators approved key legislation that will provide the necessary funding to keep the U.S. FDA operating efficiently.

FDA’s commissioner told staff in an email that he intends to delay any labor reductions until the end of September unless Congress authorizes its user fee program to provide the necessary funding.